ArticleBMC complementary medicine and therapies2025
Antiatherogenic and plaque stabilizing effects of saffron ethanolic extract in atherosclerotic rabbits.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of tocotrienol-rich fraction (TRF) on lipid profile in hyperlipidemic experimental animal model: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Exploring the mechanism of saffron in treating viral myocarditis using network pharmacology and molecular docking.Medicine · 2026Article
- Targeting pathological chemokines in CVD: the role of saffron on CCL2 and CXCL8.Molecular biology reports · 2026Review
- Saffron as a natural modulator of reverse cholesterol transport genes in atherosclerotic rabbits, with molecular docking insights.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSaffron, the dried stigma of the flower Crocus sativus L., has been shown to have therapeutic effects on cardiovascular diseases. Several studies have explored the impact of saffron on atherosclerosis. However, the mechanism underlying the plaque-stabilizing and antiatherosclerotic effects of saffron has not been widely studied. Therefore, this study aimed to investigate the mechanism of the antiatherosclerotic and plaque-stabilizing effects of saffron ethanolic extract in experimentally induced atherosclerotic rabbits.
methodsNew Zealand White rabbits were fed a 1% high-cholesterol diet (HCD) for 8 weeks to induce established atherosclerosis. The rabbits were then treated with 50 or 100 mg/kg/day saffron ethanolic extract (SAF), simvastatin (2.5 mg/kg/day) or placebo for another 8 weeks. Body weight, lipid profile, percentage of atherosclerotic lesions, immunohistochemical analysis, and quantitative real-time polymerase chain reaction were performed at baseline, after high-cholesterol diet feeding, and after the intervention.
resultsThe results showed that SAF had no significant effect on body weight. However, treatment with both doses of SAF markedly attenuated the levels of low-density lipoprotein (LDL) and total cholesterol (TC) in atherosclerotic rabbits. Higher doses of SAF markedly reduced atherosclerotic lesions in rabbit aortas. Additionally, SAF suppressed the tissue and gene expression of adhesion molecules and pro-inflammatory biomarkers in the aorta. SAF also reduced MMP-9 tissue expression in the aortas of atherosclerotic rabbits, thereby increasing plaque stability.
conclusionsOur findings suggest that saffron ethanolic extract exhibits therapeutic potential in rabbits with HCD-induced atherosclerosis. This effect may be associated with the modulation of inflammatory pathways, leading to reduced expression of pro-inflammatory cytokines, endothelial activation markers, and matrix metalloproteinases. The observed reduction in vascular inflammation and endothelial activation may contribute to improved lipid profiles, decreased atherosclerotic lesion severity, and enhanced plaque stability. While these findings highlight the potential of saffron ethanolic extract as an adjunctive treatment for atherosclerosis, further studies are warranted to clarify its direct effects on lipid metabolism and underlying molecular mechanisms. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.